Evogene Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Total revenues for the first nine months of 2025 were approximately $3.5 million, down from $4 million in the same period of 2024. Q3 2025 revenues were about $300,000, a decline from $1.7 million year-over-year.

Operating Loss: The operating loss for the first nine months was approximately $8.8 million, significantly improved from $15.3 million in the same period last year. Q3 operating loss was approximately $2.7 million, down from $5.9 million in Q3 2024.

Net Loss: The net loss for the first nine months was approximately $2.5 million, compared to $18 million in the previous year. Q3 net income was approximately $5.2 million, a turnaround from a net loss of $8.2 million in Q3 2024, primarily due to income from discontinued operations.

Cash Position: As of September 30, 2025, cash and short-term deposits totaled approximately $16 million, bolstered by the sale of Lavie Bio's assets.

2Strategic Updates and Business Highlights

Strategic Shift: Evogene is transitioning towards computational chemistry, focusing on generative design of small molecules for pharmaceutical and agricultural applications through its ChemPass AI technology.

Cost Reduction: A significant organizational change and cost reduction plan was implemented, leading to lower operating expenses of approximately $2.9 million in Q3 2025, down from $6.6 million in Q3 2024.

Subsidiary Developments: The sale of Lavie Bio's majority assets to ICL was completed in July 2025, contributing to a gain of approximately $6.4 million recognized in the financials. AgPlenus continues to work on developing new herbicides and fungicides in collaboration with major industry players like Bayer and Corteva.

3Forward Guidance and Outlook

Future Collaborations: Evogene anticipates announcing new collaborations in the pharmaceutical sector, particularly with biotech companies, in early 2026.

Growth Potential: The company aims to leverage its ChemPass AI technology to enhance drug discovery success rates and expects to continue expanding its partnerships in both the pharmaceutical and agricultural sectors.

Market Positioning: Evogene is focused on establishing itself as a leader in AI-driven small molecule design, with a strong emphasis on addressing real-world challenges in both industries.

4Bad News, Challenges, or Points of Concern

Revenue Decline: The decrease in revenue, particularly from AgPlenus, raises concerns about the sustainability of income streams, especially following the one-time payment from Bayer in early 2024.

Market Risks: The ongoing geopolitical situation in Israel, including the war between Israel and Hamas, poses risks to operational stability and could impact future business activities.

Dependency on Collaborations: The success of Evogene's strategy heavily relies on securing partnerships in the pharmaceutical sector, which may take time to materialize.

5Notable Q&A Insights

Interest in ChemPass AI: Management noted increased interest in their AI technology following industry developments, such as NVIDIA and Eli Lilly's partnership, indicating a growing market for AI in drug discovery.

IR Strategy: There was acknowledgment of the need for improved investor relations efforts, with plans for roadshows and participation in professional events to enhance visibility.

Upcoming Catalysts: Expected announcements include new collaborations in both pharma and agriculture, as well as potential partnerships with major tech firms to enhance ChemPass AI capabilities. Overall, Evogene's Q3 2025 results reflect a strategic pivot towards computational chemistry and AI-driven solutions, with significant improvements in financial metrics but ongoing challenges in revenue generation and market risks.